Ginkgo Bioworks and Cambrium Partner to Revolutionize Cell Factory Engineering
April 20, 2023
Trending News 🌥️
Ginkgo Bioworks ($NYSE:DNA), a leader in the biotech industry and a provider of software-guided organism engineering, has recently partnered with Cambrium, a company specializing in cell factory engineering, to revolutionize cell factory engineering. This announcement has been met with widespread enthusiasm and has been credited for the surge of Ginkgo’s share price. Ginkgo Bioworks is a company that designs and engineers custom microbes for customers across multiple industries, including food, health, energy, and materials. It utilizes proprietary software and hardware to design and build biological systems that function as engineered organisms. The company’s product offerings range from Genome Foundry to DNA Foundry, making gene synthesis, genetic engineering, and DNA sequencing services available to their customers.
With a mission to make biology easier to engineer, Ginkgo Bioworks is committed to revolutionizing the way biology is engineered and applied in the world. This successful collaboration with Cambrium will enable Ginkgo Bioworks to further accelerate and scale its cell factory engineering capabilities. Furthermore, this collaboration will enable Ginkgo Bioworks to create new, efficient pathways for producing products from microbes that were previously not possible. The announcement of this collaboration has been met with widespread enthusiasm and has been credited for the surge of Ginkgo’s share price, making it a great opportunity for investors.
Price History
Through this partnership, GINKGO BIOWORKS and Cambrium will be combining their expertise in the engineering of microbes to create a groundbreaking process that will significantly improve the efficiency and speed of engineering microbes for industrial use. With this groundbreaking process, the companies aim to reduce the time and cost of engineering microbes for industrial applications. The news of this partnership drove GINKGO BIOWORKS stock up 2.5% from its prior closing price to $1.2, as investors began to anticipate the potential returns from this new technology. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…
| Total Revenues | Net Income | Net Margin |
| 477.71 | -2.11k | -462.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…
| Operations | Investing | Financing |
| -252.2 | -67.39 | 95.34 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.54k | 803.04 | 0.86 |
Key Ratios Snapshot
Some of the financial key ratios for Ginkgo Bioworks are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 106.6% | – | -444.1% |
| FCF Margin | ROE | ROA |
| -63.7% | -83.6% | -52.2% |
Analysis
At GoodWhale, we recently analyzed GINKGO BIOWORKS‘s financials to help investors decide whether or not to invest in the company. After a thorough review of their financials, we gave them a medium risk rating. This means that while there are some risks associated with investing in GINKGO BIOWORKS, the overall risk level is still relatively low. We also detected 3 risk warnings in their balance sheet, cashflow statement, and financial journal. While these warnings are important to consider, it doesn’t necessarily mean that GINKGO BIOWORKS is a bad investment. Rather, it’s simply something to keep an eye on as you monitor their financials. If you’d like to learn more about the warnings we found and how they might affect your decision to invest in GINKGO BIOWORKS, please register on goodwhale.com. We’d be happy to provide you with more information and help you make an informed decision. More…
Peers
The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.
– Abivax SA ($OTCPK:AAVXF)
Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
– Atreca Inc ($NASDAQ:BCEL)
Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.
– Kiromic BioPharma Inc ($NASDAQ:KRBP)
Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Summary
Ginkgo Bioworks is a synthetic biology company whose stock has recently been volatile due to its collaboration with Cambrium. The partnership is focused on engineering cell factories, which could be a great investment opportunity for investors. Ginkgo’s technology and capabilities make it a great choice for developing industrial products that are more sustainable and efficient. The company has the potential to disrupt many industries, including biopharmaceuticals and agriculture.
Ginkgo is also working with other partners to develop tools for the digital transformation of biology. Investing in Ginkgo Bioworks may bring a great return as the company is well-positioned to reap immense benefits from its collaboration with Cambrium and its other partnerships.
